Study Shows Statistically Significant Survival Gain – 16.2 Months Versus 14.16 – in What Novocure Says Is the First New Treatment in Decades for Locally Advanced Pancreatic Cancer
Current section
Study shows statistically significant survival gain – 16.2 months versus 14.16 – in what Novocure says is the first new treatment in decades for locally advanced pancreatic cancer
Print in a simple, ad-free format
Ad-free and in a comfortable reading format
The U.S. Food and Drug Administration has approved Israel-founded company Novocure to market a wearable device for the treatment of advanced pancreatic cancer, one of the deadliest forms of the disease.
Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
Pancreatic cancer is the fifth most common cause of cancer deaths in the UK, according to the NHS
Discovery could revolutionise early identification and intervention for the deadly disease
Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit
It is estimated that 1,250 people a year could benefit from the new drug
